RxDoctor Payments Data

Tamera Pace, NP

Adult Health · Nashville, TNNPI 1427045897

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.5% of the total across 927 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,143in general payments, 2019–2025

Across 927 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • AbbVie$1K
  • Pfizer$970
  • Amgen$937
  • Lilly USA, LLC$932
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$15,90699%
  • Education$2371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk145$2,758
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC75$1,417
AbbVie83$1,145
Pfizer60$970
Amgen(2 entities)57$937
Lilly USA, LLC67$932
Otsuka America Pharmaceutical, Inc.33$653
Novartis35$597
Kowa Pharmaceuticals America, Inc.49$573
GSK34$511
Bayer22$472
AstraZeneca26$464
Boehringer Ingelheim22$405
Astellas Pharma US Inc10$313
Merck21$309
Biohaven Pharmaceutical Holding Company Ltd.10$288
Lundbeck LLC12$286
Esperion Therapeutics, Inc.15$277
Johnson & Johnson14$241
Sumitomo Pharma America, Inc.13$235
Exact Sciences10$163
Biohaven Pharmaceuticals, Inc.8$158
Amarin Pharma, Inc.8$150
Teva Pharmaceuticals USA, Inc.5$142
Takeda Pharmaceuticals U.S.A., Inc.8$124
Xeris Pharmaceuticals, Inc.6$120
Shield Therapeutics Inc6$112
Abbott6$112
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$103
Phathom Pharmaceuticals, Inc.5$100
Eisai Inc.6$100
Sunovion Pharmaceuticals Inc.6$91
Avanir Pharmaceuticals, Inc.4$78
Alkermes, Inc.3$70
Axsome Therapeutics, Inc.2$58
Zealand Pharma US, Inc.2$49
Idorsia Pharmaceuticals US Inc3$45
Nestle Healthcare Nutrition Inc.2$42
Sanofi-aventis U.S. LLC2$38
Neurocrine Biosciences, Inc.1$38
Dexcom, Inc.2$35
Medtronic2$33
Corcept Therapeutics1$33
Nevro Corp.1$31
Impel Pharmaceuticals Inc.2$30
Biogen2$30
Vanda Pharmaceuticals Inc.2$28
Jazz Pharmaceuticals Inc.1$28
Azurity Pharmaceuticals, Inc.2$27
Medicure Pharma Inc.1$26
Mayne Pharma Commercial LLC1$24
Inspire Medical Systems, Inc.1$21
Clarus Therapeutics Inc.2$20
Phadia US Inc.1$18
Biodelivery Sciences International, Inc.1$16
IBSA Pharma Inc.1$14
Galderma Laboratories, L.p.1$14
Insulet Corporation1$13
PBG Puerto Rico LLC1$13
Vistapharm, Inc.1$13

How this compares

$16,143 in reported general payments places this provider in the 95th percentile of 352 adult health providers in Tennessee.

See all adult health providers in Tennessee

Medicare billing

Part B allowed, 2024
$49,816
Medicare patients
106
Services billed
1,519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide125$153,324
JardianceEmpagliflozin94$79,081
Tresiba Flextouch U-200Insulin Degludec43$75,259
JanuviaSitagliptin Phosphate81$64,491
XareltoRivaroxaban50$42,662
Repatha SureclickEvolocumab62$38,673
EliquisApixaban43$34,799
UbrelvyUbrogepant23$34,095
GlyxambiEmpagliflozin/Linagliptin32$25,001
TradjentaLinagliptin13$18,390
Praluent PenAlirocumab28$18,042
FarxigaDapagliflozin Propanediol17$17,556
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,553
TrulicityDulaglutide15$13,831
Breo ElliptaFluticasone/Vilanterol19$11,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,758$153,324125 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$405$122,472139 claims
MerckJanuvia$309$64,49181 claims
AbbVieUbrelvy, Fetzima, Linzess, Synthroid$1,145$53,10885 claims
Johnson & JohnsonXarelto$241$42,66250 claims
PfizerEliquis$970$34,79943 claims
GSKTrelegy Ellipta, Breo Ellipta$511$25,66242 claims
AstraZenecaFarxiga$464$17,55617 claims
Lilly USA, LLCTrulicity$932$13,83115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 352 adult health providers in Tennessee.

Other adult health in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →